170 related articles for article (PubMed ID: 37426835)
21. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
Maitland HS
Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
[TBL] [Abstract][Full Text] [Related]
22. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
Newland A; McDonald V
Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
[TBL] [Abstract][Full Text] [Related]
23. Older Adults and Immune Thrombocytopenia: Considerations for the Clinician.
Crickx E; Mahévas M; Michel M; Godeau B
Clin Interv Aging; 2023; 18():115-130. PubMed ID: 36726813
[TBL] [Abstract][Full Text] [Related]
24. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
Kolonić SO; Patekar MB; Milunović V
Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
[TBL] [Abstract][Full Text] [Related]
25. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez TJ; Bermejo N; Cardesa-Cabrera R; Martínez V; Aguilar-Monserrate G; Pérez Segura G; García AD; Luis-Navarro J; Lakhwani S; Acedo N; Lozano ML; Bernat S; Torres-Tienza A; Ruano A; Jarque I; Galán Alvarez P; Benet Campos C; Marcellini-Antonio S; Jimenez-Bárcenas R; Martínez-Carballeira D; de Miguel Llorente D; Perona Blázquez Á; González-Gascón-Y-Marín I; Lopez-Ansoar E; Alonso Alonso JM; Bengochea-Casado ML; Díaz Gálvez FJ; Moretó A; Moreno G; Hernández-Martin R; de Cabo E; Davila-Valls J; Cuesta A; Pastoriza Cruz C; Hermida G; García C; Pozas-Mañas MA; Aguilar-Franco C; Fernandez-Jimenez D; Navas-Elorza B; López-Santamaría Castro C; Lorenzo Vizcaya A; Ortín X; Pintos MG; Piernas S; Díaz-Santa J; Soto-Ortega I; Provan D; García-Donas Gabaldón G
Blood; 2024 Jun; ():. PubMed ID: 38843478
[TBL] [Abstract][Full Text] [Related]
26. Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice.
Song F; Al-Samkari H
J Blood Med; 2021; 12():653-664. PubMed ID: 34345191
[TBL] [Abstract][Full Text] [Related]
27. Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Newland A; Lee EJ; McDonald V; Bussel JB
Immunotherapy; 2018 Jan; 10(1):9-25. PubMed ID: 28967793
[TBL] [Abstract][Full Text] [Related]
28. Current and emerging treatments for immune thrombocytopenia.
Dou X; Yang R
Expert Rev Hematol; 2019 Sep; 12(9):723-732. PubMed ID: 31237783
[No Abstract] [Full Text] [Related]
29. Diagnosis and treatment of immune thrombocytopenia.
Červinek L
Vnitr Lek; 2018; 64(5):526-529. PubMed ID: 30193522
[TBL] [Abstract][Full Text] [Related]
30. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
[TBL] [Abstract][Full Text] [Related]
31. ITP and international guidelines: what do we know, what do we need?
Rodeghiero F; Ruggeri M
Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
[TBL] [Abstract][Full Text] [Related]
32. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
[TBL] [Abstract][Full Text] [Related]
33. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of ITP].
Yokoyama K
Rinsho Ketsueki; 2021; 62(8):1229-1235. PubMed ID: 34497211
[TBL] [Abstract][Full Text] [Related]
35. New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.
Clemons Bankston P; Al-Horani RA
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31226783
[TBL] [Abstract][Full Text] [Related]
36. Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP).
Chen F; McDonald V; Newland A
Expert Opin Biol Ther; 2021 Nov; 21(11):1383-1393. PubMed ID: 34313512
[TBL] [Abstract][Full Text] [Related]
37. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment.
Ghanima W; Gernsheimer T; Kuter DJ
Blood; 2021 May; 137(20):2736-2744. PubMed ID: 33827138
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
[TBL] [Abstract][Full Text] [Related]
39. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
[TBL] [Abstract][Full Text] [Related]
40. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
Cooper N; Hill QA; Grainger J; Westwood JP; Bradbury C; Provan D; Thachil J; Ramscar N; Roy A
Acta Haematol; 2021; 144(4):418-426. PubMed ID: 33789275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]